Adaptive immunity represents nature’s most effective search engine: Disease protection arises through a beneficial antibody providing a selective advantage over a myriad of different antibodies
click to view larger image
We make antibodies to counter complex diseases, such as cancer and neurodegenerative diseases.
Alchemab identifies these naturally occurring protective antibodies by mining the antibody repertoires of individuals who are resistant to or recovered from disease. We are developing the antibodies into therapeutic products for broader use in patients who lack this protective response and are suffering from hard-to-treat diseases.
Our unique approach starts by identifying groups of resilient individuals, such as long-term survivors of cancer or people with slow-to-progress neurodegenerative disorders.
Their antibody repertoires are then deeply sequenced, resulting in billions of antibody sequences that feed into our computational drug discovery engine.
We use advanced analytical tools to find groups of functionally related protective antibodies that are convergent across the resilient population only.
Convergent antibodies are selected to enter a suite of phenotypic assays to understand their function and identify the antibodies with the best therapeutic properties.
This unique discovery process receives inspiration from nature to find novel drug targets and naturally-optimized therapeutic antibodies.
East Side, Office 1.02
London N1C 4AX
Meditrina Building 260
Babraham Research Campus